Capecitabine-induced hypertriglyceridemia and hyperglycemia: Two cases

Pharmacology

Volumn 90, Issue 3-4, 2012, Pages 212-215

  Duman, Berna Bozkurt ^a   Paydas, Semra ^a   Tetiker, Tamer ^b   Gunald, Meral ^a   Afsar, Cigdem Usul ^a   Erçolak, Vehbi ^a   Haksöyler, Veysel ^c   Dilli, Merve Şimşek ^c  

^a CUKUROVA UNIVERSITY   (Turkey)

^b Department of Endocrinology ^*  (Turkey)

^c Balcali Hospital   (Turkey)

Author keywords

Breast cancer; Capecitabine; Colorectal cancer; Hypertriglyceridemia

Indexed keywords

ANTILIPEMIC AGENT; AROMATASE INHIBITOR; CAPECITABINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAMOXIFEN; ZOLEDRONIC ACID;

ADULT; ANAMNESIS; BONE METASTASIS; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CASE REPORT; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; REVIEW;

ANTIMETABOLITES, ANTINEOPLASTIC; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; MIDDLE AGED;

EID: 84867205702     PISSN: 00317012     EISSN: 14230313     Source Type: Journal    
DOI: 10.1159/000342382     Document Type: Review

References (15)

1. Blum J L, Jones SE, Buzdar AU, et al: Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999;17:485-493.
2. Koutras AK, Habeos IG, Vagenakis AG, Kalofonos HP: Capecitabine-induced hypertriglyceridemia: a report of two cases. Anticancer Res 2006;26:2249-2251.
3. Kurt M, Babaoglu MO, Yasar U, Shorbagi A, Guler N: Capecitabine-induced severe hypertriglyceridemia: report of two cases. Ann Pharmacother 2006;40:328-331.
4. Pejic RN, Lee DT: Hypertriglyceridemia. J Am Board Fam Med 2006;19:310-316.
5. Roche Pharmaceuticals: Package insert. Xeloda (capecitabine). MoH approved leaflets, July 2007.
6. Jones KL, Valero V: Capecitabine-induced pancreatitis. Pharmacotherapy 2003;23: 1076-1078.
7. Orphanos GS, Stavrou NG, Picolos MK: Hypertriglyceridemia: an underdiagnosed side effect of capecitabine chemotherapy. Acta Oncol 2010;49:262-263.
8. Stathopoulos GP, Stergiou GS, Perrea-Kostarelis DN, et al: Influence of 5-fluorouracil on serum lipids. Acta Oncol 1995;34: 253-256.
9. Polinder-Bos HA, Kok EE, van de Wiel A, Spiering W, Wielders JP, Bloemendal HJ: Severe hypertriglyceridaemia associated with the use of capecitabine. Neth J Med 2012;70: 104-100.
10. Javot L, Spaëth D, Scala-Bertola J, Gambier N, Petitpain N, Gillet P: Severe hypertriglyceridaemia during treatment with capecitabine. Br J Cancer 2011;104:1238-1239.
11. Michie CO, Sakala M, Rivans I, Strachan MW, Clive S: The frequency and severity of capecitabine-induced hypertriglyceridaemia in routine clinical practice: a prospective study. Br J Cancer 2010;103:617-621.
12. Bar-Sela G, Haim N: Uncontrolled hypertriglyceridemia induced by capecitabine: case report and review of the literature. Cancer Chemother Pharmacol 2009;63:779-782.
13. Garg R, Angus E, Fincher S: Capecitabineinduced severe hypertriglyceridaemia and diabetes: a case report and review of the literature. Diabet Med 2009;26:1308-1309.
14. Seminara P, Losanno T, Emiliani A, Manna G: Cancer chemotherapy and cardiovascular risks: is capecitabine-induced hypertriglyceridemia a rare adverse effect? Cardiology 2010;116:42-44.
15. Miwa M, Ura M, Nishida M, et al: Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998;34:1274-1281.